2015

Reactivated CD4+Tm cells of T1D patients and siblings display an exaggerated effector phenotype with heightened sensitivity to activation-induced cell death.

Bian, M. L. Haigh, O. Munster, D. Harris, M. Cotterill, A. Miles, J. J. Vuckovic, S.

Diabetes 2015;64: 2161-2171.

2015

American Society of Blood and Marrow Transplantation, European Society of Blood and Marrow Transplantation, Blood and Marrow Transplant Clinical Trials Network, and International Myeloma Working Group Consensus Conference on Salvage Hematopoietic Cell Transplantation in Patients with Relapsed Multiple Myeloma. Biol Blood Marrow Transplant.

Giralt S, Garderet L, Durie B, Cook G, Gahrton G, Bruno B, Hari P, Lokhorst H, McCarthy P, Krishnan A, Sonneveld P, Goldschmidt H, Jagannath S, Barlogie B, Mateos M, Gimsing P, Sezer O, Mikhael J, Lu J, Dimopoulos M, Mazumder A, Palumbo A, Abonour R, Anderson K, Attal M, Blade J, Bird J, Cavo M, Comenzo R, de la Rubia J, Einsele H, Garcia-Sanz R, Hillengass J, Holstein S, Johnsen HE, Joshua D, Koehne G, Kumar S, Kyle R, Leleu X, Lonial S, Ludwig H, Nahi H, Nooka A, Orlowski R, Rajkumar V, Reiman A, Richardson P, Riva E, San Miguel J, Turreson I, Usmani S, Vesole D, Bensinger W, Qazilbash M, Efebera Y, Mohty M, Gasparreto C, Gajewski J, LeMaistre CF, Bredeson C, Moreau P, Pasquini M, Kroeger N, Stadtmauer E.

2015 Dec;21(12):2039-2051. doi: 10.1016/j.bbmt.2015.09.016. Epub 2015 Sep 30.

2015

Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation. Leuk Lymphoma.

McAuliffe S, Brown R, Catalano A, Ho PJ, Nassif N, Woodland N, Hart D, Weatherburn C, Yang S, Suen H, Paul C, Joshua D, Gibson J.

2015;56(9):2714-6. doi: 10.3109/10428194.2014.1003061. Epub 2015 Feb 17.

2015

Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy.

Anguille S, Smits EL, Bryant C, Van Acker HH, Goossens H, Lion E, Fromm PD, Hart DN, Van Tendeloo VF, Berneman ZN.

Pharmacol Rev. 2015 Oct;67(4):731-53. doi: 10.1124/pr.114.009456. Review.

2015

Practical management of myelofibrosis with ruxolitinib.

Ho PJ, Marlton P, Tam C, Stevenson W, Ritchie D, Bird R, Dunlop LC, Durrant S, Ross DM

(2015). Intern Med J 45:1221-30.

2015

The failure of immune checkpoint blockade in multiple myeloma with PD-1 inhibitors in a phase 1 study.

Suen H, Brown R, Yang S, Ho PJ, Gibson J, Joshua D

(2015). Leukemia 29:1621-2.

2015

Phospho-flow detection of constitutive and cytokine-induced pSTAT3/5, pAKT and pERK expression highlights novel prognostic biomarkers for patients with multiple myeloma.

Brown R, Yang S, Weatherburn C, Gibson J, Ho PJ, Suen H, Hart D, Joshua D

(2015) Leukemia 29:483-90.

2015

Treatment of patients with multiple myeloma who are eligible for stem cell transplantation: position statement of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Quach H, Joshua D, Ho J, Szer J, Spencer A, Harrison SJ, Mollee P, Roberts AW, Horvath N, Talulikar D, To B, Zannettino A, Brown R, Catley L, Augustson B, Jaksic W, Gibson J, Prince HM

(2015) Intern Med J 45:94-105.

2015

Management of Systemic Light Chain (AL) Amyloidosis: Recommendations of the Myeloma Foundation of Australia Medical and Scientific Advisory Group.

Weber N, Mollee P, Augustson B, Brown R, Catley L, Gibson J, Harrison S, Ho PJ, Horvath N, Jaksic W, Joshua D, Quach H, Roberts AW, Spencer A, Szer J, Talaulikar D, To B, Zannettino A, Prince HM

(2015) Intern Med J. Intern Med J. 2015 Apr;45(4):371-82.

2015

Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

Iland HJ, Collins M, Bradstock K, Supple SG, Catalano A, Hertzberg M, Browett P, Grigg A, Firkin F, Campbell LJ, Hugman A, Reynolds J, Di Iulio J, Tiley C, Taylor K, Filshie R, Seldon M, Taper J, Szer J, Moore J, Bashford J, Seymour JF for the Australasian Leukaemia and Lymphoma Group.

Lancet Haematol 2015; 2(9):e357-66.

2015

A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.

He SZ, Busfield S, Ritchie DS, Hertzberg MS, Durrant S, Lewis ID, Marlton P, McLachlan AJ, Kerridge I, Bradstock KF, Kennedy G, Boyd AW, Yeadon TM, Lopez AF, Ramshaw HS, Iland H, Bamford S, Barnden M, DeWitte M, Basser R, Roberts AW.

Leuk Lymphoma 2015; 56(5):1406-15

2015

Dendritic Cells as Pharmacological Tools For Cancer. Immunotherapy.

S Anguille, Smits E, Bryant C et al.

Pharmacological Review. 2015 Oct;67(4):731-53

2015

Contribution of chemotherapy mobilization to disease control in multiple myeloma treated with autologous hematopoietic cell transplantation.

Uy GL, Costa LJ, Hari PN, Zhang MJ3 Huang JX, Anderson KC5 Bredeson CN, Callander NS, Cornell RF, Perez MA, Dispenzieri A, Freytes CO, Gale RP, Garfall A, Gertz M, Gibson J, Hamadani M, Lazarus H5, Kalaycio ME, Kamble RT, Kharfan-Dabaja MA, Krishnan AY, Kumar SK, Kyle RA, Landau HJ, Lee CH, Maiolino A, Marks DI, Mark TM, Munker R, Nishihori T18, Olsson RF26,27, Ramanathan M, Rodriguez TE, Saad AA, Savani BN, Schiller GJ, Schouten HC, Schriber JR, Scott E, Seo S, Sharma M, Ganguly S, Stadtmauer E, Tay J, To LB, Vesole DH, Vogl DT, Wagner JL, Wirk B, Wood WA, D’Souza.

Bone Marrow Transplant. 20 Dec;50(12):1513-8. doi: 10.1038/bmt.2015.190. Epub 2015 Aug 24.

2015

A CAM do approach: The attitudes, use and disclosure of the use of Complementary and Alternative Medicine (CAM) in those with myeloma.

T King, S Grant, S Taylor, K Houteas, C Barnett, K White

(2015) Clinical Lymphoma Myeloma and Leukaemia.15(3):e317-318.